Literature DB >> 1987351

Polypharmacy among patients attending an AIDS clinic: utilization of prescribed, unorthodox, and investigational treatments.

R M Greenblatt1, H Hollander, J R McMaster, C J Henke.   

Abstract

The objective of this study was to describe the utilization and characteristics associated with the use of prescribed, over-the-counter, investigational, and unorthodox treatments among AIDS clinic patients. This report is derived from cross-sectional data obtained using structured telephone surveys. Study participants (n = 197) were recruited from the University of California, San Francisco, Medical Center AIDS clinic. One hundred eighty-nine participants (96%) received 1-24 prescription medications during the 3 months prior to interview. Those with an AIDS diagnosis received a relatively greater number of prescription drugs (p = 0.0001); an average of 5.6 prescribed medications were used by AIDS patients versus 4.8 among AIDS-related complex and 2.3 among asymptomatic patients. Thirty-one percent participated in drug trials during the 3 months before interview, including 18% who were in multiple studies. Twenty-nine percent used unorthodox treatments. Seventy-five (40%) received prescription medication from a provider other than their primary provider. A more advanced stage of illness was associated with the use of unorthodox treatments (p = 0.003): users of these treatments had a greater educational attainment than nonusers (p = 0.03) and were significantly less likely to report that their primary provider was aware of all the treatments they used (odds ratio = 2.1, p less than 0.03). We conclude that use of polypharmacy among some AIDS clinic patients is common, could create an increased risk for adverse drug reactions, and may affect clinical drug trials. Despite having decided to obtain care at a university-based clinic, many of the participants of this study also chose to receive unorthodox therapies and care from nonprimary medical providers.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1987351

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr (1988)        ISSN: 0894-9255


  9 in total

Review 1.  Complementary medicine: state of the evidence.

Authors:  C Vincent; A Furnham
Journal:  J R Soc Med       Date:  1999-04       Impact factor: 5.344

2.  Use of alternative therapists among people in care for HIV in the United States.

Authors:  Andrew S London; Carrie E Foote-Ardah; John A Fleishman; Martin F Shapiro
Journal:  Am J Public Health       Date:  2003-06       Impact factor: 9.308

3.  Introducing complementary medicine into the medical curriculum.

Authors:  H Rampes; F Sharples; S Maragh; P Fisher
Journal:  J R Soc Med       Date:  1997-01       Impact factor: 5.344

Review 4.  Polypharmacy. Pharmacokinetic perspectives.

Authors:  P K Honig; L R Cantilena
Journal:  Clin Pharmacokinet       Date:  1994-02       Impact factor: 6.447

Review 5.  Human immunodeficiency virus (HIV) infection. Does it increase susceptibility to adverse drug reactions?

Authors:  G E Harb; M A Jacobson
Journal:  Drug Saf       Date:  1993-07       Impact factor: 5.606

Review 6.  Drug interactions between prescribed and over-the-counter medication.

Authors:  P K Honig; B K Gillespie
Journal:  Drug Saf       Date:  1995-11       Impact factor: 5.606

7.  Antiretroviral adherence and use of alternative therapies among older HIV-infected adults.

Authors:  A K Wutoh; C M Brown; E K Kumoji; M S Daftary; T Jones; N A Barnes; N J Powell
Journal:  J Natl Med Assoc       Date:  2001 Jul-Aug       Impact factor: 1.798

8.  Zidovudine adherence in persons with AIDS. The relation of patient beliefs about medication to self-termination of therapy.

Authors:  M Y Smith; B D Rapkin; A Morrison; S Kammerman
Journal:  J Gen Intern Med       Date:  1997-04       Impact factor: 5.128

9.  Medicaid policies for HIV-related prescription drugs.

Authors:  R J Buchanan; S R Smith
Journal:  Health Care Financ Rev       Date:  1994
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.